search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
CONTINUING EDUCATION TEST sPLA2


-IIA—the next step to enhancing your cardiac testing panel June 2019 [This form may be photocopied. It is no longer valid for CEUs after December 31, 2020.)


1. The continued rise of cardiovascular disease (CVD) each year represents about _________ percent of all global deaths.


{a. five {b. 13 {c. 24 {d. 31


2. What percentage of CVD patients does conventional risk assessment biomarkers detect disease in?


{a. five {b. 10 {c. 15 {d. 20


3. The clinical utility of the sPLA2 been proven to be a biomarker for


{a. infection. {b. inflammation. {c. toxin exposure. {d. all of the above


4. Inflammation has been found to be a direct cause of CVD.


{a. True {b. False


5. As little as how many risk factors are taken into consideration when determining early risk assessment in individuals?


{a. one {b. three {c. five {d. seven


6. The sPLA2 -IIA test has been specifically


{a. prognosis of current CVD disease. {b. cause of CVD. {c. diagnosis of CVD disease risk. {d. all of the above


useful in determining the


7. Which family of phospholipase does sPLA2 IIA belong to?


{a. A2 {b. A1 {c. B {d. C


- -IIA test has


TEST QUESTIONS Circles must be filled in, or test will not be graded. Shade circles like this: O Not like this: O 14. Lp-PLA2


8. As well as being an inflammatory marker, sPLA2


{a. herbicide. {b. fungicide. {c. bactericide. {d. all of the above


-IIA also functions as a


{a. hydrolyses LDL to produce atherogensis. {b. acts to promote antiatherogenic { functions.


with LDL, however sPLA2 and sPLA2


-IIA both have association -IIA mainly


9. The final product(s) produced by the binding of sPLA2


{a. platelet activating factors (PAFs). {b. leukotrienes and other eicosanoids. {c. prostaglandins. {d. all of the above


-IIA to phospholipids is/are


10. Traditional cardiac markers are used to predict adverse outcomes, whereas the sPLA2


-IIA measurement can be used to {a. True {b. False 11. sPLA2


predict the inflammatory processes that can potentially lead to a cardiac event.


-IIA modification of lipoproteins


{a. atherosclerosis. {b. arteriosclerosis. {c. pulmonary embolisms. {d. petechiae.


12. sPLA2


{a. oxidation {b. hydrolysis {c. enzymatic {d. reduction


has been found to play a direct role in the development of


c. is carried by LDL to the coronary artery { wall and activates inflammation.


d. all of the above 15. Research has proven that Lp-PLA2


{a. True {b. False


has a high


association with CVD diagnosis, cardiac death, and MI.


16. Studies have shown that sPLA2


{a. decreasing immediately. {b. increasing immediately. {c. decreasing about four hours after the { procedure.


level responds by


d. increasing about four hours after the procedure.


17. What other disease has sPLA2 -IIA acts on the LDL cholesterol


membrane to produce small-dense LDL cholesterol particles through a _______________ reaction.


-IIA been


{a. sepsis {b. diabetes {c. transient ischemic attack {d. pneumonia


18. sPLA2


13. Compared to its less dense form, small particles of which type of lipid has been demonstrated in increasing the risk of coronary heart disease?


{a. Lipo-a {b. HDL {c. LDL {d. triglycerides


{a. CRP {b. WBC count {c. PCT {d. all of the above


researched on that shows promising results? -IIA has a


prognostic value and when percutaneous coronary intervention is used, the sPLA2


-IIA


-IIA has been shown to be a more


accurate biomarker than __________ in sepsis patients.


Tests can be taken online or by mail. Easy registration and payment options are available through NIU by following the links found at www.mlo-online.com/ce. PLEASE PRINT CLEARLY NAME CITY PHONE STATE ZIP MAILING ADDRESS INSTITUTION/FACILITY E-MAIL ADDRESS


Send your $20 check payable to Northern Illinois University with this form to: University Outreach Services, Northern Illinois University, DeKalb, IL 60115-2860 Phone: 815-753-0031 FEE NOT REFUNDABLE OR TRANSFERABLE


P = Poor; E = Excellent


1. To what extent did the article focus on or clarify the objectives?


P E


2. To what extent was the article well-organized and readable?


P 14 JUNE 2019 MLO-ONLINE.COM E


3. How will you use the CE units? state license


recertification


employment other


CE Licensure Information for FL and CA:


FL: Your FL license number:____________________ (required for CE credit)


CA: Accrediting Agency: 0001 (for use in submitting your CE credits to CA)


MLO and Northern Illinois University (NIU), DeKalb, IL, are co-sponsors in offering continuing education units (CEUs) for this issue’s CE article. CEUs or contact hours are granted by the College of Health and Human Sciences at Northern Illinois University, which has been approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program. Approval as a provider of continuing education programs has been granted by the state of Florida (Provider No. JP0000496). Continuing education credits awarded for successful completion of this test are acceptable for the ASCP Board of Registry Continuing Competence Recognition Program. Readers who pass the test successfully (scoring 70% or higher) will receive a certificate for 1 contact hour of P.A.C.E.®


credit. Participants should allow three to five weeks for receipt of certificate. The fee for this continuing education test is $20. This test was prepared by Amanda Voelker, MPH, MT(ASCP), MLS, Clinical Education Coordinator, School of HealthStudies, Northern Illinois University, DeKalb, IL. HOME WORK


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48